New Drug Approvals
New drug approvals - January 2024
13 February 2024
Audiences
Healthcare professional
Industry member
Product-type
Therapeutic Products
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Please click here (opens in new tab) for a list of summary reports of benefit-risk assessments.
Table caption
Product Name | GENCEBOK SOLUTION FOR INFUSION 10MG/ML |
|---|---|
Active Ingredient (Strength) | Caffeine Citrate(10.00mg/ml) |
Application type | NDA-2 |
Product Registrant | AXXESSBIO PTE. LTD. |
Date of Approval | 16/01/2024 |
Registration No. | SIN16929P |
Indications: Treatment of primary apnoea of premature newborns. | |
Table caption
Product Name | LUMIGAN PF (BIMATOPROST OPHTHALMIC SOLUTION) 0.03% |
|---|---|
Active Ingredient (Strength) | Bimatoprost(0.3 mg/mL) |
Application type | NDA-2 |
Product Registrant | ABBVIE PTE. LTD. |
Date of Approval | 30/01/2024 |
Registration No. | SIN16938P |
Indications: LUMIGAN® Preservative Free 0.03% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. | |